Asieh Heirani-Tabasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Asieh Heirani-Tabasi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Amir Keshvari
Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3 shared publicationsMohammad Reza Keramati
Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications- Alireza Hadizadeh
Division of Urogynecology, University of Chicago Pritzker School of Medicine, NorthShore University HealthSystem, Skokie, USA
2 shared publications Alireza Kazemeini
Colorectal Surgery Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsBehnam Behboudi
Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsHojjatollah Nazari
School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia
2 shared publications
Latest Publications
- 6 November 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (6) , 065038
A microfluidic liver-like model for antiepileptic drugs hepatotoxicity evaluation
Drug-Induced Liver Injury (DILI) is the leading cause of late-stage drug failure and withdrawal of medications from the market. This underscores the urgent need for new in vitro liver models that better recapitulate physiologically relevant conditions and provide controlled physical and biochemical parameters for drug toxicity testing. While advanced, complex liver-on-a-chip systems have been in use for some years, this study presents a simplified microfluidic model for technically comparing static and dynamic culture conditions using a hepatocyte-like cell line for drug toxicity testing. In this study, a dual-compartment microfluidic device comprising a dynamic flow channel and a cell culture chamber was designed to mimic the liver’s microstructure. The device’s membrane-based design enabled the investigation of cell-media interactions and replication of hepatic Disse space, with comparisons made between static and dynamic conditions. The chip design was evaluated using computational models of glucose consumption and shear stress, which yielded an optimal flow rate of 50 μL/h. HepG2 cells cultured within the chip were assessed via live/dead staining and metabolic function assays, including responses to three antiepileptic drugs at physiological doses, to evaluate hepatotoxicity. Under dynamic conditions, cell viability and function improved significantly, simulating a continuous supply of nutrients and oxygen, as well as mechanical shear stress signaling. Among the tested drugs, sodium valproate (500 μM) induced the least hepatotoxicity, whereas carbamazepine and phenytoin led to a ∼60% reduction in hepatic function over one week. Although structurally and functionally less complex than existing liver-on-a-chip platforms, these findings suggest that this liver-chip platform is a simple yet useful tool for drug screening and hepatotoxicity assessment.
- 6 November 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (6) , 065038
A microfluidic liver-like model for antiepileptic drugs hepatotoxicity evaluation
Drug-Induced Liver Injury (DILI) is the leading cause of late-stage drug failure and withdrawal of medications from the market. This underscores the urgent need for new in vitro liver models that better recapitulate physiologically relevant conditions and provide controlled physical and biochemical parameters for drug toxicity testing. While advanced, complex liver-on-a-chip systems have been in use for some years, this study presents a simplified microfluidic model for technically comparing static and dynamic culture conditions using a hepatocyte-like cell line for drug toxicity testing. In this study, a dual-compartment microfluidic device comprising a dynamic flow channel and a cell culture chamber was designed to mimic the liver’s microstructure. The device’s membrane-based design enabled the investigation of cell-media interactions and replication of hepatic Disse space, with comparisons made between static and dynamic conditions. The chip design was evaluated using computational models of glucose consumption and shear stress, which yielded an optimal flow rate of 50 μL/h. HepG2 cells cultured within the chip were assessed via live/dead staining and metabolic function assays, including responses to three antiepileptic drugs at physiological doses, to evaluate hepatotoxicity. Under dynamic conditions, cell viability and function improved significantly, simulating a continuous supply of nutrients and oxygen, as well as mechanical shear stress signaling. Among the tested drugs, sodium valproate (500 μM) induced the least hepatotoxicity, whereas carbamazepine and phenytoin led to a ∼60% reduction in hepatic function over one week. Although structurally and functionally less complex than existing liver-on-a-chip platforms, these findings suggest that this liver-chip platform is a simple yet useful tool for drug screening and hepatotoxicity assessment.
- 6 September 2024
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 67 (12) , 1564-1575
Localized Administration of Mesenchymal Stem Cell–Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn’s Disease: A Phase II Clinical Trial
BACKGROUND: Crohn’s disease perianal fistulas are often resistant to standard anti–tumor necrosis factor-α therapies. Mesenchymal stem cell–derived exosomes are extracellular vesicles with highly potent anti-inflammatory effects, and the previous phase of this study demonstrated their safety in the treatment of refractory perianal fistulas. OBJECTIVE: To evaluate the efficacy of mesenchymal stem cell–derived exosomes for the treatment of refractory perianal fistulas. DESIGN: Nonrandomized, nonblinded single-center phase II clinical trial. SETTINGS: Tertiary university hospital. PATIENTS: Twenty-three patients were enrolled, 20 of whom completed the study. Refractory perianal fistula was defined as resistance to at least 1 course of treatment with anti–tumor necrosis factor-α therapy. INTERVENTIONS: After clinical assessment and MRI, the patients received general anesthesia, and 5 mL of exosome solution was injected directly into the fistula tracts. The injections were repeated 3 times at 2-month intervals, and patients were followed monthly for 6 months after the last injection. Tissue samples from the tracts were obtained before each injection and subjected to immunohistopathological assessment. MRI data were obtained before and 6 months after the last injection. MAIN OUTCOME MEASURES: The primary outcome of this study was fistula tract closure on clinical examination and MRI. The secondary outcome was an improvement in the discharge from the tracts. RESULTS: Fistula tracts were fully closed in 12 patients (60%). Four patients showed clinical improvement, with some tracts remaining open, and 4 patients were completely resistant to treatment. A total of 43 fistula tracts were treated during the trial, 30 of which (69.7%) showed complete closure. Histopathological analysis revealed substantial reductions in local inflammation and signs of enhanced tissue regeneration. Immunohistochemical analysis of CD68, CD20, and CD31 reaffirmed these results. CONCLUSIONS: Mesenchymal stem cell–derived exosomes are safe and effective for treating refractory perianal fistulas in patients with Crohn’s disease. See Video Abstract. ADMINISTRACIÓN LOCALIZADA DE EXOSOMAS DERIVADOS DE CÉLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FÍSTULA PERIANAL REFRACTARIA EN PACIENTES CON ENFERMEDAD DE CROHN: ENSAYO CLÍNICO DE FASE II: ANTECEDENTES: Las fístulas perianales de la enfermedad de Crohn a menudo son resistentes a las terapias anti-TNF-α estándares. Los exosomas derivados de células madre mesenquimales (MSC) son vesículas extracelulares que tienen efectos antiinflamatorios muy potentes, y la fase anterior de este estudio demostró su seguridad en el tratamiento de fístulas perianales refractarias. OBJETIVO: Evaluar la eficacia de los exosomas derivados de MSC para el tratamiento de fístulas perianales refractarias. DISEÑO: Ensayo clínico de fase II, no aleatorizado y no ciego, unicéntrico. LUGARES: Hospital universitario terciario. PACIENTES: Se inscribieron veintitrés pacientes, 20 de los cuales completaron el estudio. La fístula perianal refractaria se definió como la resistencia a al menos un ciclo de tratamiento con terapia anti-TNF-α. INTERVENCIONES: Después de la evaluación clínica y la resonancia magnética, los pacientes fueron sometidos a anestesia general y se inyectaron 5 ml de solución de exosoma directamente en los trayectos de la fístula. Las inyecciones se repitieron tres veces a intervalos de 2 meses y los pacientes fueron seguidos mensualmente durante 6 meses después de la última inyección. Se obtuvieron muestras de tejido de los tractos antes de cada inyección y se sometieron a evaluación inmunohistopatológica. Los datos de imágenes de resonancia magnética se obtuvieron antes y seis meses después de la última inyección. PRINCIPALES MEDIDAS DE RESULTADO: El resultado primario de este estudio fue el cierre del trayecto de la fístula en el examen clínico y la imagen de resonancia magnética. El resultado secundario fue una mejora en la descarga de los tractos. RESULTADOS: Los trayectos de la fístula se cerraron completamente en 12 (60%) de los pacientes. Cuatro pacientes mostraron mejoría clínica, algunos tractos permanecieron abiertos y cuatro pacientes fueron completamente resistentes al tratamiento. Durante el ensayo se trataron un total de 43 trayectos fistulosos, 30 (69,7%) de los cuales mostraron un cierre completo. El análisis histopatológico reveló reducciones sustanciales en la inflamación local y signos de una mayor regeneración tisular. El análisis inmunohistoquímico del grupo de diferenciación 68, 20 y 31 reafirmó estos resultados. CONCLUSIONES: Los exosomas derivados de MSC son seguros y eficaces para el tratamiento de fístulas perianales refractarias en pacientes con enfermedad de Crohn. (Traducción—Dr. Aurian Garcia Gonzalez)
- 6 September 2024
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 67 (12) , 1564-1575
Localized Administration of Mesenchymal Stem Cell–Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn’s Disease: A Phase II Clinical Trial
BACKGROUND: Crohn’s disease perianal fistulas are often resistant to standard anti–tumor necrosis factor-α therapies. Mesenchymal stem cell–derived exosomes are extracellular vesicles with highly potent anti-inflammatory effects, and the previous phase of this study demonstrated their safety in the treatment of refractory perianal fistulas. OBJECTIVE: To evaluate the efficacy of mesenchymal stem cell–derived exosomes for the treatment of refractory perianal fistulas. DESIGN: Nonrandomized, nonblinded single-center phase II clinical trial. SETTINGS: Tertiary university hospital. PATIENTS: Twenty-three patients were enrolled, 20 of whom completed the study. Refractory perianal fistula was defined as resistance to at least 1 course of treatment with anti–tumor necrosis factor-α therapy. INTERVENTIONS: After clinical assessment and MRI, the patients received general anesthesia, and 5 mL of exosome solution was injected directly into the fistula tracts. The injections were repeated 3 times at 2-month intervals, and patients were followed monthly for 6 months after the last injection. Tissue samples from the tracts were obtained before each injection and subjected to immunohistopathological assessment. MRI data were obtained before and 6 months after the last injection. MAIN OUTCOME MEASURES: The primary outcome of this study was fistula tract closure on clinical examination and MRI. The secondary outcome was an improvement in the discharge from the tracts. RESULTS: Fistula tracts were fully closed in 12 patients (60%). Four patients showed clinical improvement, with some tracts remaining open, and 4 patients were completely resistant to treatment. A total of 43 fistula tracts were treated during the trial, 30 of which (69.7%) showed complete closure. Histopathological analysis revealed substantial reductions in local inflammation and signs of enhanced tissue regeneration. Immunohistochemical analysis of CD68, CD20, and CD31 reaffirmed these results. CONCLUSIONS: Mesenchymal stem cell–derived exosomes are safe and effective for treating refractory perianal fistulas in patients with Crohn’s disease. See Video Abstract. ADMINISTRACIÓN LOCALIZADA DE EXOSOMAS DERIVADOS DE CÉLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FÍSTULA PERIANAL REFRACTARIA EN PACIENTES CON ENFERMEDAD DE CROHN: ENSAYO CLÍNICO DE FASE II: ANTECEDENTES: Las fístulas perianales de la enfermedad de Crohn a menudo son resistentes a las terapias anti-TNF-α estándares. Los exosomas derivados de células madre mesenquimales (MSC) son vesículas extracelulares que tienen efectos antiinflamatorios muy potentes, y la fase anterior de este estudio demostró su seguridad en el tratamiento de fístulas perianales refractarias. OBJETIVO: Evaluar la eficacia de los exosomas derivados de MSC para el tratamiento de fístulas perianales refractarias. DISEÑO: Ensayo clínico de fase II, no aleatorizado y no ciego, unicéntrico. LUGARES: Hospital universitario terciario. PACIENTES: Se inscribieron veintitrés pacientes, 20 de los cuales completaron el estudio. La fístula perianal refractaria se definió como la resistencia a al menos un ciclo de tratamiento con terapia anti-TNF-α. INTERVENCIONES: Después de la evaluación clínica y la resonancia magnética, los pacientes fueron sometidos a anestesia general y se inyectaron 5 ml de solución de exosoma directamente en los trayectos de la fístula. Las inyecciones se repitieron tres veces a intervalos de 2 meses y los pacientes fueron seguidos mensualmente durante 6 meses después de la última inyección. Se obtuvieron muestras de tejido de los tractos antes de cada inyección y se sometieron a evaluación inmunohistopatológica. Los datos de imágenes de resonancia magnética se obtuvieron antes y seis meses después de la última inyección. PRINCIPALES MEDIDAS DE RESULTADO: El resultado primario de este estudio fue el cierre del trayecto de la fístula en el examen clínico y la imagen de resonancia magnética. El resultado secundario fue una mejora en la descarga de los tractos. RESULTADOS: Los trayectos de la fístula se cerraron completamente en 12 (60%) de los pacientes. Cuatro pacientes mostraron mejoría clínica, algunos tractos permanecieron abiertos y cuatro pacientes fueron completamente resistentes al tratamiento. Durante el ensayo se trataron un total de 43 trayectos fistulosos, 30 (69,7%) de los cuales mostraron un cierre completo. El análisis histopatológico reveló reducciones sustanciales en la inflamación local y signos de una mayor regeneración tisular. El análisis inmunohistoquímico del grupo de diferenciación 68, 20 y 31 reafirmó estos resultados. CONCLUSIONES: Los exosomas derivados de MSC son seguros y eficaces para el tratamiento de fístulas perianales refractarias en pacientes con enfermedad de Crohn. (Traducción—Dr. Aurian Garcia Gonzalez)
- Open Access
- 16 June 2022
- Published by Wiley
Evaluating the Safety and Efficacy of MSCs-derived Exosomes for Treatment of Refractory Perianal Fistula in IBD patients; Clinical Trial Phase I
Background and objectives: Exosomes therapy is a promising technique that can decrease the concern related to the fate of transplanted stem cells to the fistula location. The unique properties of mesenchymal stem cells (MSCs)-derived exosomes can improve fistula healing because of their high ability to regulate and modify immune responses. This project aims to examine the safety and efficacy of implementing MSCs-exosomes in treating refractory fistulas in inflammatory bowel disease (IBD) patients. Methods : The exosomes were isolated from umbilical cord-derived MSCs and characterized using flow cytometry, western blotting, and transmittance electron microscope (TEM). Five patients (three men and two women) with refractory perianal Crohn's disease with an average age of 35.4 years old were included. The patients did not match the exclusion criteria, and the presence of refractory fistulas was the main inclusion criteria. These patients have their exosomes injections in the operation room. The therapy responses of patients were assessed using physical examination, face-to-face interviews, computerized tomography (CT) scan, and magnetic resonance imaging (MRI) six months later. Result : The Following injection, patients reported a 70% improvement on average. Two patients claimed complete healing after exosome injections, while one patient reported no improvement and active discharge from the fistula site. In addition, five patients reported no adverse effects, both systemic or on the injection site. Conclusion : Injection of exosomes extracted from MSCs shows total safety and a satisfactory therapeutic impact, as shown in this and other research, and could play a significant role in the treatment of gastrointestinal fistulas in the future.
- 16 June 2022
- Published by Wiley
Open AccessEvaluating the Safety and Efficacy of MSCs-derived Exosomes for Treatment of Refractory Perianal Fistula in IBD patients; Clinical Trial Phase I
Background and objectives: Exosomes therapy is a promising technique that can decrease the concern related to the fate of transplanted stem cells to the fistula location. The unique properties of mesenchymal stem cells (MSCs)-derived exosomes can improve fistula healing because of their high ability to regulate and modify immune responses. This project aims to examine the safety and efficacy of implementing MSCs-exosomes in treating refractory fistulas in inflammatory bowel disease (IBD) patients. Methods : The exosomes were isolated from umbilical cord-derived MSCs and characterized using flow cytometry, western blotting, and transmittance electron microscope (TEM). Five patients (three men and two women) with refractory perianal Crohn's disease with an average age of 35.4 years old were included. The patients did not match the exclusion criteria, and the presence of refractory fistulas was the main inclusion criteria. These patients have their exosomes injections in the operation room. The therapy responses of patients were assessed using physical examination, face-to-face interviews, computerized tomography (CT) scan, and magnetic resonance imaging (MRI) six months later. Result : The Following injection, patients reported a 70% improvement on average. Two patients claimed complete healing after exosome injections, while one patient reported no improvement and active discharge from the fistula site. In addition, five patients reported no adverse effects, both systemic or on the injection site. Conclusion : Injection of exosomes extracted from MSCs shows total safety and a satisfactory therapeutic impact, as shown in this and other research, and could play a significant role in the treatment of gastrointestinal fistulas in the future.
- Open Access
- 31 December 2021
- Published by MDPI AG in Biosensors
- Vol. 12 (1) , 20
Microfluidic-Based Droplets for Advanced Regenerative Medicine: Current Challenges and Future Trends
Microfluidics is a promising approach for the facile and large-scale fabrication of monodispersed droplets for various applications in biomedicine. This technology has demonstrated great potential to address the limitations of regenerative medicine. Microfluidics provides safe, accurate, reliable, and cost-effective methods for encapsulating different stem cells, gametes, biomaterials, biomolecules, reagents, genes, and nanoparticles inside picoliter-sized droplets or droplet-derived microgels for different applications. Moreover, microenvironments made using such droplets can mimic niches of stem cells for cell therapy purposes, simulate native extracellular matrix (ECM) for tissue engineering applications, and remove challenges in cell encapsulation and three-dimensional (3D) culture methods. The fabrication of droplets using microfluidics also provides controllable microenvironments for manipulating gametes, fertilization, and embryo cultures for reproductive medicine. This review focuses on the relevant studies, and the latest progress in applying droplets in stem cell therapy, tissue engineering, reproductive biology, and gene therapy are separately evaluated. In the end, we discuss the challenges ahead in the field of microfluidics-based droplets for advanced regenerative medicine.
- 31 December 2021
- Published by MDPI AG in Biosensors
- Vol. 12 (1) , 20
Open AccessMicrofluidic-Based Droplets for Advanced Regenerative Medicine: Current Challenges and Future Trends
Microfluidics is a promising approach for the facile and large-scale fabrication of monodispersed droplets for various applications in biomedicine. This technology has demonstrated great potential to address the limitations of regenerative medicine. Microfluidics provides safe, accurate, reliable, and cost-effective methods for encapsulating different stem cells, gametes, biomaterials, biomolecules, reagents, genes, and nanoparticles inside picoliter-sized droplets or droplet-derived microgels for different applications. Moreover, microenvironments made using such droplets can mimic niches of stem cells for cell therapy purposes, simulate native extracellular matrix (ECM) for tissue engineering applications, and remove challenges in cell encapsulation and three-dimensional (3D) culture methods. The fabrication of droplets using microfluidics also provides controllable microenvironments for manipulating gametes, fertilization, and embryo cultures for reproductive medicine. This review focuses on the relevant studies, and the latest progress in applying droplets in stem cell therapy, tissue engineering, reproductive biology, and gene therapy are separately evaluated. In the end, we discuss the challenges ahead in the field of microfluidics-based droplets for advanced regenerative medicine.
- 22 July 2021
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 28 (1) , 133-142
Advanced Regenerative Medicine Strategies for Treatment of Perianal Fistula in Crohn’s Disease
Regenerative medicine is an emerging therapeutic method that aims to reconstruct tissues and organs. This advanced therapeutic approach has demonstrated great potential in addressing the limitations of medical and surgical procedures for treating perineal fistula in patients with Crohn’s disease. Recent developments in stem cell technology have led to a massive good manufacturing practices (GMPs) production of various stem cells, including mesenchymal and embryonic cells, along with induction of pluripotent stem cells to repair damaged tissues in the fistula. The recent advances in separation and purification of exosomes, as biologic nanovesicles carrying anti-inflammatory and regenerative agents, have made them powerful tools to treat this inflammatory disease. Further, tremendous advances in nanotechnology, biomaterials, and scaffold fabrication methods enable tissue engineering methods to synthesize tissue-like structures to assist surgical techniques. This review focuses on advanced regenerative-based methods including stem cell therapy, exosome therapy, and tissue engineering used in the treatment of perianal fistula. Relevant in vitro and in vivo studies and the latest innovations in implementation of regenerative medicine for this disease are also separately reviewed. Additionally, current challenges regarding implementation of g stem cells, exosomes, and tissue engineering methods for bridging the gaps between laboratory findings and clinic application will be discussed.
- 22 July 2021
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 28 (1) , 133-142
Advanced Regenerative Medicine Strategies for Treatment of Perianal Fistula in Crohn’s Disease
Regenerative medicine is an emerging therapeutic method that aims to reconstruct tissues and organs. This advanced therapeutic approach has demonstrated great potential in addressing the limitations of medical and surgical procedures for treating perineal fistula in patients with Crohn’s disease. Recent developments in stem cell technology have led to a massive good manufacturing practices (GMPs) production of various stem cells, including mesenchymal and embryonic cells, along with induction of pluripotent stem cells to repair damaged tissues in the fistula. The recent advances in separation and purification of exosomes, as biologic nanovesicles carrying anti-inflammatory and regenerative agents, have made them powerful tools to treat this inflammatory disease. Further, tremendous advances in nanotechnology, biomaterials, and scaffold fabrication methods enable tissue engineering methods to synthesize tissue-like structures to assist surgical techniques. This review focuses on advanced regenerative-based methods including stem cell therapy, exosome therapy, and tissue engineering used in the treatment of perianal fistula. Relevant in vitro and in vivo studies and the latest innovations in implementation of regenerative medicine for this disease are also separately reviewed. Additionally, current challenges regarding implementation of g stem cells, exosomes, and tissue engineering methods for bridging the gaps between laboratory findings and clinic application will be discussed.
- 19 August 2020
- Published by Springer Nature in Cell and Tissue Banking
- Vol. 21 (4) , 643-653
Comparison the effects of hypoxia-mimicking agents on migration-related signaling pathways in mesenchymal stem cells
Adipose-derived mesenchymal stem cells (Ad-MSCs) have been designated as the promising agents for clinical applications for easy accessibility, multi-linage differentiation and immunomodulation capacity. Despite this, optimal cell delivery conditions have remained as a clinical challenge and improvement of stem cell homing to the target organs is being considered as a major strategy in cell therapy systemic injection. It has been shown that homing of mesenchymal stem cells are increased when treated with physical or chemical hypoxia-mimicking factors, however, efficiency of different agents remained to be determined. In this study, hypoxia-mimicking agents, including valproic acid (VPA), cobalt chloride (CoCl2) and deferoxamine (DFX) were examined to determine whether they are able to activate signaling molecules involved in migration of Ad-MSCs in vitro. We report that Ad-MSCs treated by DFX resulted in a significantly enhanced mRNA expression of MAPK4 (associated with MAPK signaling pathway), INPP4B (associated with Inositol polyphosphate pathway), VEGF-A and VEGF-C (associated with cytokine–cytokine receptor pathways), IL-8 and its receptor, CXCR2 (associated with IL-8 signaling pathway). While the cells treated with VPA did not show such effects and CoCl2 only upregulated VEGF-A and VEGF-C gene expression. Furthermore, results of wound-healing assays showed migration capacity of Ad-MSCs treated with DFX significantly increased 8 and 24 h of the treatment. This study provides credible evidence around DFX, which might be an effective drug for pharmacological preconditioning of Ad-MSCs to boost their homing capacity and regeneration of damaged tissues though, activation of the migration-related signaling pathways.
- 19 August 2020
- Published by Springer Nature in Cell and Tissue Banking
- Vol. 21 (4) , 643-653
Comparison the effects of hypoxia-mimicking agents on migration-related signaling pathways in mesenchymal stem cells
Adipose-derived mesenchymal stem cells (Ad-MSCs) have been designated as the promising agents for clinical applications for easy accessibility, multi-linage differentiation and immunomodulation capacity. Despite this, optimal cell delivery conditions have remained as a clinical challenge and improvement of stem cell homing to the target organs is being considered as a major strategy in cell therapy systemic injection. It has been shown that homing of mesenchymal stem cells are increased when treated with physical or chemical hypoxia-mimicking factors, however, efficiency of different agents remained to be determined. In this study, hypoxia-mimicking agents, including valproic acid (VPA), cobalt chloride (CoCl2) and deferoxamine (DFX) were examined to determine whether they are able to activate signaling molecules involved in migration of Ad-MSCs in vitro. We report that Ad-MSCs treated by DFX resulted in a significantly enhanced mRNA expression of MAPK4 (associated with MAPK signaling pathway), INPP4B (associated with Inositol polyphosphate pathway), VEGF-A and VEGF-C (associated with cytokine–cytokine receptor pathways), IL-8 and its receptor, CXCR2 (associated with IL-8 signaling pathway). While the cells treated with VPA did not show such effects and CoCl2 only upregulated VEGF-A and VEGF-C gene expression. Furthermore, results of wound-healing assays showed migration capacity of Ad-MSCs treated with DFX significantly increased 8 and 24 h of the treatment. This study provides credible evidence around DFX, which might be an effective drug for pharmacological preconditioning of Ad-MSCs to boost their homing capacity and regeneration of damaged tissues though, activation of the migration-related signaling pathways.
- Open Access
- 29 February 2016
- Published by DiscoverSys, Inc. in The Cancer Press
- Vol. 2 (1) , 23
CXCR4: A Potential Biomarker for Targeted Cancer Therapy in the Future
- 29 February 2016
- Published by DiscoverSys, Inc. in The Cancer Press
- Vol. 2 (1) , 23
Open AccessCXCR4: A Potential Biomarker for Targeted Cancer Therapy in the Future
- Open Access
- 2 January 2016
- Published by DiscoverSys, Inc. in Cell Therapy and Regenerative Medicine Journal
- Vol. 1 (1) , 20
Therapeutic Potential of CXCR4/SDF-1 Axis in Acute Myocardial Infarction
- 2 January 2016
- Published by DiscoverSys, Inc. in Cell Therapy and Regenerative Medicine Journal
- Vol. 1 (1) , 20
Open AccessTherapeutic Potential of CXCR4/SDF-1 Axis in Acute Myocardial Infarction